Evidence map›Paper›PMID 30150413›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2018

BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export.

Kao Chin Ngeow, Hans J Friedrichsen, Linxin Li, Zhiqiang Zeng, Sarah Andrews, Laurent Volpon, Hannah Brunsdon, Georgina Berridge, Sarah Picaud, Roman Fischer and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 81 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. VersatileProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Melanin Inhibitory Effect ofJournal of microbiology and biotechnology · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Research square · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 3 countries.

Kao Chin NgeowLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Headington, OX3 7DQ Oxford, United Kingdom.ORCID 0000-0002-7765-1632
Hans J FriedrichsenLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Headington, OX3 7DQ Oxford, United Kingdom.
Linxin LiLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Headington, OX3 7DQ Oxford, United Kingdom.
Zhiqiang ZengMedical Research Council Human Genetics Unit & Edinburgh Cancer Research Centre, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, EH4 2XR Edinburgh, United Kingdom.
Sarah AndrewsLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Headington, OX3 7DQ Oxford, United Kingdom.
Laurent VolponInstitute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC H3T 1J4, Canada.
Hannah BrunsdonMedical Research Council Human Genetics Unit & Edinburgh Cancer Research Centre, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, EH4 2XR Edinburgh, United Kingdom.
Georgina BerridgeLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Headington, OX3 7DQ Oxford, United Kingdom.
Sarah PicaudStructural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Headington, OX3 7DQ Oxford, United Kingdom.
Roman FischerDiscovery Proteomics Facility, Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Headington, OX3 7FZ Oxford, United Kingdom.
Richard LisleLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Headington, OX3 7DQ Oxford, United Kingdom.
Stefan KnappStructural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Headington, OX3 7DQ Oxford, United Kingdom.
Panagis FilippakopoulosStructural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Headington, OX3 7DQ Oxford, United Kingdom.
Helen KnowlesBotnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Headington, OX3 7HE Oxford, United Kingdom.
Eiríkur SteingrímssonDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland.
Katherine L B BordenInstitute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC H3T 1J4, Canada.
E Elizabeth PattonMedical Research Council Human Genetics Unit & Edinburgh Cancer Research Centre, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, EH4 2XR Edinburgh, United Kingdom.
Colin R GodingLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Headington, OX3 7DQ Oxford, United Kingdom; colin.goding@ludwig.ox.ac.uk.
University of Oxford · GBEdinburgh Cancer Research · GBInstitute for Research in Immunology and Cancer · CANuffield Orthopaedic Centre · GBUniversity of Iceland · IS

Funding

Tumor Assessment CoreP01CA128814 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI SMITH, JEFFREY W · 2009 to 2020
$19.1M
PROMYELOCYTIC LEUKEMIA PROTEINS ROLE IN APOPTOSISR01CA080728 · NCI · UNIVERSITY OF MONTREAL · PI KATHERINE L B BORDEN · 1999 to 2026
$5.3M
Molecular Mechanisms of eIF4E Mediated TransformationR01CA098571 · NCI · UNIVERSITY OF MONTREAL · PI BORDEN, KATHERINE L B, GUZMAN, MONICA L · 2003 to 2025
$5.0M
Arthritis Research UK MP/19200Cancer Research UK C38302/A12981Medical Research Council MC_PC_U127585840Medical Research Council MC_U127585840Medical Research Council MC_UU_00007/9Medical Research Council MR/N010051/1NCI NIH HHS P01 CA128814NCI NIH HHS R01 CA080728NCI NIH HHS R01 CA098571Versus Arthritis 19200Wellcome TrustWellcome Trust 095751/Z/11/Z
6 · The paper itself

Abstract

The close integration of the MAPK, PI3K, and WNT signaling pathways underpins much of development and is deregulated in cancer. In principle, combinatorial posttranslational modification of key lineage-specific transcription factors would be an effective means to integrate critical signaling events. Understanding how this might be achieved is central to deciphering the impact of microenvironmental cues in development and disease. The microphthalmia-associated transcription factor MITF plays a crucial role in the development of melanocytes, the retinal pigment epithelium, osteoclasts, and mast cells and acts as a lineage survival oncogene in melanoma. MITF coordinates survival, differentiation, cell-cycle progression, cell migration, metabolism, and lysosome biogenesis. However, how the activity of this key transcription factor is controlled remains poorly understood. Here, we show that GSK3, downstream from both the PI3K and Wnt pathways, and BRAF/MAPK signaling converges to control MITF nuclear export. Phosphorylation of the melanocyte MITF-M isoform in response to BRAF/MAPK signaling primes for phosphorylation by GSK3, a kinase inhibited by both PI3K and Wnt signaling. Dual phosphorylation, but not monophosphorylation, then promotes MITF nuclear export by activating a previously unrecognized hydrophobic export signal. Nonmelanocyte MITF isoforms exhibit poor regulation by MAPK signaling, but instead their export is controlled by mTOR. We uncover here an unanticipated mode of MITF regulation that integrates the output of key developmental and cancer-associated signaling pathways to gate MITF flux through the import-export cycle. The results have significant implications for our understanding of melanoma progression and stem cell renewal.

Indexed as

MAP Kinase Signaling SystemActive Transport, Cell NucleusAnimalsCell Line, TumorCell NucleusCells, CulturedGlycogen Synthase Kinase 3HeLa CellsHumansMelanomaMicrophthalmia-Associated Transcription FactorMutationPhosphorylationProtein BindingProto-Oncogene Proteins B-rafBRAF protein, humanGlycogen Synthase Kinase 3Microphthalmia-Associated Transcription FactorMITF protein, humanProto-Oncogene Proteins B-rafGSK3MAPKmelanomaMITFnuclear export

Identifiers

PMID30150413
PMCPMC6140509
OpenAlexW2888885038

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.